StockNews.com Begins Coverage on Can-Fite BioPharma (NYSE:CANF)

Stock analysts at StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANFGet Free Report) in a note issued to investors on Monday. The firm set a “sell” rating on the stock.

A number of other analysts have also recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Can-Fite BioPharma in a report on Tuesday, November 12th. D. Boral Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, December 31st.

Get Our Latest Stock Report on Can-Fite BioPharma

Can-Fite BioPharma Stock Down 4.8 %

Shares of NYSE CANF opened at $1.39 on Monday. Can-Fite BioPharma has a fifty-two week low of $1.29 and a fifty-two week high of $4.69. The firm has a market cap of $4.92 million, a PE ratio of -0.78 and a beta of 1.33. The business has a 50 day moving average price of $1.61 and a two-hundred day moving average price of $2.12.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers increased its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANFFree Report) by 58.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,880 shares of the company’s stock after purchasing an additional 9,935 shares during the period. Rhumbline Advisers owned 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.

Featured Stories

Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.